Gilead, Lakefront complete Ouro Medicines acquisition
Source: SeekingAlpha
2026-06-04 16:59:30 ET
More on Gilead Sciences
- Gilead: 'Hold' On Biktarvy Sales Growth And MM Drug Development Program
- Gilead Sciences, Inc. (GILD) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript
- Why Gilead Sciences Is Now A Hold (Rating Upgrade)
- Regeneron, Gilead therapies eyed as potential Ebola treatments by WHO
- Gilead's Hepcludex wins FDA approval for chronic HDV infection
Read the full article on Seeking Alpha
For further details see:
Gilead, Lakefront complete Ouro Medicines acquisition
Gilead Sciences Inc.
NASDAQ: GILD
GILD Trading
1.87% G/L:
$131.47 Last:
3,249,390 Volume:
$130.09 Open:
GILD Latest News
June 05, 2026 03:00:00 am
Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa
GILD Stock Data
$185,419,569,657
1,228,272,827
0.07%
1237
N/A
Pharmaceuticals
Healthcare
US
Foster City
